Peripheral tolerance is the set of controls that restrain mature immune cells after they have developed, which helps stop them reacting against the body's own tissues. Tumours can use the same controls to avoid attack, and a treatment that releases them can also harm healthy organs.
Central tolerance acts during lymphocyte development, in T-cell selection in the thymus and B-cell development in bone marrow. Peripheral tolerance acts on mature cells in tissues and lymphoid organs. The two names say when and where restraint operates, not that they are two complete filters that remove every self-reactive receptor. For T cells, tolerance mechanisms that operate in the thymus before the cells mature and circulate are called central tolerance, but not every self-antigen is made in the thymus, so central tolerance alone is insufficient and additional mechanisms restrain mature circulating T cells (Xing and Hogquist, 2012). For B cells, tolerance regulated at the immature B-cell stage in the bone marrow is called central tolerance and works through clonal deletion and receptor editing, while mechanisms that act after B cells leave the bone marrow were described as not fail-safe and mostly reversible (Nemazee, 2017). Several mechanisms contribute: anergy (reduced responsiveness), deletion (removal by cell death), suppression by regulatory T cells, inhibitory pathways and limited supporting signals. Deletion and restraint differ, because a deleted clone is gone and a restrained clone may remain and respond differently under defined conditions. In transgenic mice, cross-presentation of a self-antigen led to deletion of autoreactive CD8 T cells, and adding CD4 helper cells impaired that deletion and caused diabetes in 68 per cent of mice, whereas the CD8 cells alone did not (Kurts et al., 1997). In mice, transferring CD4 cells depleted of CD25-positive cells into athymic recipients caused multiple autoimmune diseases, and giving back CD4-positive CD25-positive cells within a limited period prevented them in a dose-dependent way (Sakaguchi et al., 1995). A separate mechanism acts on ligand supply: CTLA-4 captured CD80 and CD86 from opposing cells by trans-endocytosis, impairing costimulation through CD28 (Qureshi et al., 2011).
In plain words · The first immune brake ever targeted for cancer; releasing it won a Nobel Prize and cures a fraction of melanomas.
Showing the target this term concerns: CTLA-4.
Shares Immune system, T cell.
Shares Immune system, T cell.
Shares Immune checkpoint, Immune-related adverse events (irAEs), CTLA-4.
Shares Immune system, T cell.
Shares Immune system, T cell, Immune checkpoint, Immune-related adverse events (irAEs).
Shares Immune system, Immune checkpoint, CTLA-4.
Shares Immune system, Immune checkpoint.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/